Premium
Structure‐Based Grafting, Mutation, and Optimization of Peptide Inhibitors to Fit in the Active Pocket of Human Secreted Phospholipase A2: Find New Use of Old Peptide Agents with Anti‐Inflammatory Activity
Author(s) -
Zhan Chengye,
Li Shusheng,
Zhong Qiang,
Zhou Daixing
Publication year - 2015
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12424
Subject(s) - peptide , active site , phospholipase a , biochemistry , peptide sequence , mutant , enzyme , amino acid , chemistry , phospholipase , phospholipase a2 , in vitro , biological activity , gene
Phospholipase A 2 ( PLA 2 ) is a key enzyme in the production of diverse mediators of inflammatory conditions, which possesses an open active pocket that is physicochemically compatible with a variety of small‐molecule substrates and peptide inhibitors. Although various peptides and peptide analogues have been identified to have inhibitory activity against PLA 2 originated from animals and plants, only very few were designed for human secreted PLA 2 (hs PLA 2 ), an attractive target of inflammatory arthritis. Considering that the catalytic domains of PLA 2 family members across different species are highly conserved in primary sequence, advanced structure, and biological function, in this study, we proposed a synthetic pipeline to implement structure‐based grafting, mutation, and optimization of peptide ligands from the snake PLA 2 –peptide complex crystal structures into the active pocket of apo hs PLA 2 structure to computationally generate a large number of potential peptide inhibitors for hs PLA 2 , and the hs PLA 2 inhibitory potency of few highly promising candidates arising from the theoretical analysis was determined. As might be expected, three peptides FLSFK , FLVYK , and FISYR showed relatively high inhibitory capability against hs PLA 2 , and other three ALSYK , LVFYA , and KGAILGFM were also modestly potent as they can suppress the enzymatic activity with observable doses. Further, the designed peptide FLVYK with highest potency was carried out with structure‐guided modification based on its atomic interactions with hs PLA 2 using the computationally modeled structure data, consequently resulting in a dual‐point mutant E L I YK with significantly increased activity.